Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clenbuterol + nadolol
- Development stage
- Unknown
- Lead developer
- CuraSen Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CST-103 + CST-107 (also known as CuraCN or clenbuterol + nadolol) is an oral combination therapy developed by CuraSen Therapeutics for the treatment of neurodegenerative and psychiatric disorders, including Parkinson's disease, mild cognitive impairment (MCI), dementia with Lewy bodies, and major depressive disorder. The combination consists of CST-103 (clenbuterol), a brain-permeant beta-2 adrenergic receptor (β2-AR) agonist, and CST-107 (nadolol), a brain-sparing (peripherally restricted) beta-adrenergic receptor blocker. By co-administering nadolol, the peripheral cardiometabolic side effects of clenbuterol (such as tachycardia, palpitations, and tremors) are minimized, while clenbuterol's central nervous system effects—such as restoring adrenergic stimulus to the brain to compensate for locus coeruleus degeneration—are preserved. The therapy has demonstrated cognitive and mood benefits in Phase 2 clinical trials.
- Other names
- clenbuterol and nadololclenbuterol/nadolol
02
Targets
ADRB1 (β1)ADRB2 (β2)
Beyond the preview
Go deeper on clenbuterol + nadolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clenbuterol + nadolol.